The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Mental Health (NIMH) invite grant applications for Alzheimer's disease (AD) drug discovery.*
AD is one of the most persistent and devastating disorders of old age because it eventually leads to a complete loss of memory and the ability to function independently. An estimated four and a half million people in the United States have AD in its various stages and a projected 14 million people and their families could be affected by AD by the middle of this century if no new treatments are developed. The purpose of this announcement is to stimulate the discovery, development, and preclinical testing in cellular, tissue, and animal models of novel compounds for the prevention and treatment of the cognitive impairment and behavioral symptoms associated with AD.
The development of compounds for ameliorating, modifying, or improving potential aberrations in neuronal cellular communication mechanisms is encouraged. These compounds should be designed to affect fundamental processes, such as the neuronal dysfunction, death, and loss of connectivity associated with the disease by targeting molecules and mechanisms such as neurotransmitters, neuromodulators, and neurotrophins; receptors and ion channels; second and third messenger systems; all facets of relevant amyloid precursor protein, amyloid beta protein, and tau neurobiology; protein synthesis, aggregation, and degradation; energy utilization; and oxidative, immunological, and inflammatory mechanisms.
For more information, potential applicants should contact Dr. Diane Murphy, Program Director, Neurodegeneration Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2222, Bethesda, MD 20892; telephone: 301-496-5680; fax: 301-480-1080; e-mail: firstname.lastname@example.org.
*For a more detailed description of this announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PAS-06-261.html.